EP3212290A4 - SERPIN FUSION POLYPEPTIDES AND METHODS OF USE - Google Patents

SERPIN FUSION POLYPEPTIDES AND METHODS OF USE Download PDF

Info

Publication number: EP3212290A4
Authority: EP; European Patent Office
Prior art keywords: methods; fusion polypeptides; serpin fusion; serpin; polypeptides
Prior art date: 2014-10-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP15854670.5A

Other languages

German (de)

French (fr)

Other versions

EP3212290A1 (en

Inventor

Brendan P. Eckelman

John C. Timmer

Quinn Deveraux

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sanofi Aatd Inc

Original Assignee

Inhibrx Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-27

Filing date

2015-10-27

Publication date

2019-01-23

2014-10-27 Priority claimed from US14/524,832 external-priority patent/US10400029B2/en

2015-10-27 Application filed by Inhibrx Inc filed Critical Inhibrx Inc

2017-09-06 Publication of EP3212290A1 publication Critical patent/EP3212290A1/en

2019-01-23 Publication of EP3212290A4 publication Critical patent/EP3212290A4/en

Status Pending legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Obesity (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)

EP15854670.5A 2014-10-27 2015-10-27 SERPIN FUSION POLYPEPTIDES AND METHODS OF USE Pending EP3212290A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US14/524,832 US10400029B2 (en)	2011-06-28	2014-10-27	Serpin fusion polypeptides and methods of use thereof
PCT/US2015/057533 WO2016069574A1 (en)	2014-10-27	2015-10-27	Serpin fusion polypeptides and methods of use thereof

Publications (2)

Publication Number	Publication Date
EP3212290A1 EP3212290A1 (en)	2017-09-06
EP3212290A4 true EP3212290A4 (en)	2019-01-23

Family

ID=55858243

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP15854670.5A Pending EP3212290A4 (en)	2014-10-27	2015-10-27	SERPIN FUSION POLYPEPTIDES AND METHODS OF USE

Country Status (15)

Country	Link
EP (1)	EP3212290A4 (en)
JP (2)	JP6737781B2 (en)
KR (2)	KR20170091096A (en)
CN (2)	CN114316068A (en)
AU (3)	AU2015339507B2 (en)
BR (1)	BR112017008525A2 (en)
CA (1)	CA2965151A1 (en)
HK (1)	HK1244460A1 (en)
IL (2)	IL251799B2 (en)
MX (2)	MX2017005467A (en)
NZ (1)	NZ769391A (en)
RU (1)	RU2746550C2 (en)
SG (2)	SG11201703390SA (en)
UA (1)	UA127305C2 (en)
WO (1)	WO2016069574A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US12497441B2 (en)	2018-10-29	2025-12-16	Spin Therapeutics, Llc	Compositions and methods for alpha-1-antitrypsin disorders
CN111989340B (en) *	2018-11-18	2025-07-15	杭州博虎生物科技有限公司	A recombinant human interleukin-10 fusion protein and its application
CN112315897A (en) *	2020-11-04	2021-02-05	深圳前海鹰岗生物科技有限公司	Polymer microneedle for treating acute gout attack by inhibiting release of cell inflammatory reaction and preparation method
WO2022133521A1 (en) *	2020-12-21	2022-06-30	Macquarie University	Treatment of glaucoma
GB202102258D0 (en)	2021-02-17	2021-03-31	Arecor Ltd	Novel composition
US20240139296A1 (en) *	2021-03-03	2024-05-02	Formycon Ag	Formulations of ace2 fc fusion proteins
CN113325181A (en) *	2021-04-25	2021-08-31	苏州市立医院(北区)	Application of serine protease inhibitor in marker for early warning of sepsis
CN114874333B (en) *	2021-10-18	2025-01-24	深圳科兴药业有限公司	A growth hormone fusion protein and its application
WO2023225513A1 (en)	2022-05-16	2023-11-23	Inhibrx, Inc.	Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject
AU2024219542B1 (en) *	2023-05-05	2024-10-03	Ashley Maurice Buckle	Novel therapeutic polypeptide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004092219A2 (en) *	2003-04-10	2004-10-28	Protein Design Labs, Inc	Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2013003641A2 (en) *	2011-06-28	2013-01-03	Inhibrx Llc	Serpin fusion polypeptides and methods of use thereof
US20130058919A1 (en) *	2002-03-01	2013-03-07	Xencor, Inc.	Optimized Fc Variants and Methods for their Generation
WO2014001325A1 (en) *	2012-06-27	2014-01-03	F. Hoffmann-La Roche Ag	Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002537810A (en) *	1999-03-01	2002-11-12	ヒューマンジノームサイエンシーズ，インコーポレイテッド	Human serpin protein
CN102020700A (en) *	2003-07-18	2011-04-20	沃泰克斯药物股份有限公司	Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
JP2007504144A (en) *	2003-08-26	2007-03-01	ザリージェンツオブザユニバーシティーオブコロラドアボディーコーポレイト	Serine protease activity inhibitors and methods for their use in the treatment and composition of bacterial infections
US8802820B2 (en) *	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
EP2325206B1 (en) *	2004-11-12	2014-03-19	Xencor, Inc.	Fc variants with altered binding to fcrn
EP1910542B1 (en) *	2005-07-22	2009-12-02	Five Prime Therapeutics, Inc.	Compositions and methods of treating disease with fgfr fusion proteins
CN101443357A (en) *	2005-08-12	2009-05-27	先灵公司	MCP1 fusion
CA2729012A1 (en) *	2008-06-27	2009-12-30	Amgen Inc.	Ang-2 inhibition to treat multiple sclerosis
SG10201407908VA (en) *	2008-12-19	2015-01-29	Macrogenics Inc	Covalent diabodies and uses thereof
HUE033205T2 (en) *	2010-12-23	2017-11-28	Janssen Biotech Inc	Active, protease-resistant antibody-FC mutant
HUE041335T2 (en) *	2011-03-29	2019-05-28	Roche Glycart Ag	Antibody fc variants
IN2013MN02442A (en) *	2011-06-28	2015-06-12	Inhibrx Llc
KR20140137347A (en) *	2012-01-10	2014-12-02	더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트	Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
TW201402611A (en) *	2012-06-21	2014-01-16	Univ Indiana Res & Tech Corp	Incretin receptor ligand polypeptide Fc-region fusion polypeptides and conjugates with altered Fc-effector function
CA2876096A1 (en) *	2012-08-02	2014-02-06	Petra Rueger	Method for producing soluble fcr as fc-fusion with inert immunoglobulin fc-region and uses thereof
JP6345688B2 (en) *	2012-12-05	2018-06-20	ソラ・バイオサイエンシズ・エルエルシー	Protein expression enhancing polypeptide

2015
- 2015-10-27 SG SG11201703390SA patent/SG11201703390SA/en unknown
- 2015-10-27 IL IL251799A patent/IL251799B2/en unknown
- 2015-10-27 KR KR1020177014414A patent/KR20170091096A/en not_active Ceased
- 2015-10-27 HK HK18103148.5A patent/HK1244460A1/en unknown
- 2015-10-27 UA UAA201705128A patent/UA127305C2/en unknown
- 2015-10-27 EP EP15854670.5A patent/EP3212290A4/en active Pending
- 2015-10-27 CN CN202111439584.9A patent/CN114316068A/en active Pending
- 2015-10-27 NZ NZ769391A patent/NZ769391A/en unknown
- 2015-10-27 MX MX2017005467A patent/MX2017005467A/en unknown
- 2015-10-27 JP JP2017522654A patent/JP6737781B2/en active Active
- 2015-10-27 WO PCT/US2015/057533 patent/WO2016069574A1/en not_active Ceased
- 2015-10-27 AU AU2015339507A patent/AU2015339507B2/en active Active
- 2015-10-27 IL IL308589A patent/IL308589A/en unknown
- 2015-10-27 SG SG10201903142RA patent/SG10201903142RA/en unknown
- 2015-10-27 BR BR112017008525-9A patent/BR112017008525A2/en active Search and Examination
- 2015-10-27 CA CA2965151A patent/CA2965151A1/en active Pending
- 2015-10-27 RU RU2017118325A patent/RU2746550C2/en active
- 2015-10-27 CN CN201580071331.7A patent/CN107206257A/en active Pending
- 2015-10-27 KR KR1020237043666A patent/KR20240005109A/en not_active Ceased
2017
- 2017-04-26 MX MX2021012047A patent/MX2021012047A/en unknown
2020
- 2020-07-16 JP JP2020121953A patent/JP2020180157A/en active Pending
2021
- 2021-09-28 AU AU2021240153A patent/AU2021240153A1/en not_active Abandoned
2024
- 2024-05-29 AU AU2024203586A patent/AU2024203586A1/en active Pending

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130058919A1 (en) *	2002-03-01	2013-03-07	Xencor, Inc.	Optimized Fc Variants and Methods for their Generation
WO2004092219A2 (en) *	2003-04-10	2004-10-28	Protein Design Labs, Inc	Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2013003641A2 (en) *	2011-06-28	2013-01-03	Inhibrx Llc	Serpin fusion polypeptides and methods of use thereof
WO2014001325A1 (en) *	2012-06-27	2014-01-03	F. Hoffmann-La Roche Ag	Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2016069574A1 *

Also Published As

Publication number	Publication date
JP6737781B2 (en)	2020-08-12
AU2024203586A1 (en)	2024-06-20
BR112017008525A2 (en)	2018-01-30
CN114316068A (en)	2022-04-12
RU2017118325A3 (en)	2019-03-21
IL251799B1 (en)	2023-12-01
AU2015339507A1 (en)	2017-05-11
SG11201703390SA (en)	2017-05-30
SG10201903142RA (en)	2019-05-30
JP2020180157A (en)	2020-11-05
NZ769391A (en)	2024-12-20
CA2965151A1 (en)	2016-05-06
AU2015339507B2 (en)	2021-07-01
UA127305C2 (en)	2023-07-19
NZ731223A (en)	2024-12-20
JP2017537888A (en)	2017-12-21
KR20240005109A (en)	2024-01-11
KR20170091096A (en)	2017-08-08
RU2746550C2 (en)	2021-04-15
WO2016069574A1 (en)	2016-05-06
HK1244460A1 (en)	2018-08-10
EP3212290A1 (en)	2017-09-06
IL251799A0 (en)	2017-06-29
IL251799B2 (en)	2024-04-01
CN107206257A (en)	2017-09-26
MX2021012047A (en)	2021-11-03
RU2017118325A (en)	2018-11-29
MX2017005467A (en)	2017-11-30
IL308589A (en)	2024-01-01
AU2021240153A1 (en)	2021-10-28

Publication	Publication Date	Title
EP3390624A4 (en)	2019-07-10	MODIFIED TARGETED MODIFICATION POLYPEPTIDES AND METHODS OF USE
IL254165A0 (en)	2017-10-31	Immunomodulatory fusion proteins and their uses
EP3436048A4 (en)	2019-11-27	NEOANTIGENES AND METHODS OF USE
EP3212290A4 (en)	2019-01-23	SERPIN FUSION POLYPEPTIDES AND METHODS OF USE
EP3394065A4 (en)	2019-07-10	TETRAHYDROPYRANYL-AMINO-PYRROLOPYRIMIDINONE AND METHODS OF USE THEREFOR
MA55097A (en)	2022-01-05	OXYSTEROLS AND METHODS OF USE THEREOF
EP3436030A4 (en)	2019-11-06	CHIMERIC RECEPTORS AND METHODS OF USE
EP2971000A4 (en)	2016-11-23	PHI-4 POLYPEPTIDES AND METHODS OF USE
EP3325821C0 (en)	2023-06-07	CLAMPS AND CLOSURE SYSTEM
EP3319612A4 (en)	2019-03-06	OXYSTEOLS AND METHODS OF USE
EP3319610A4 (en)	2019-03-06	OXYSTEOLS AND METHODS OF USE
EP3455263A4 (en)	2020-01-01	CD40L-FC FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
EP3303435A4 (en)	2019-02-20	HYDROFLUOROLEFINS AND METHODS OF USE THEREFOR
DK3578547T3 (en)	2021-08-23	SULPHONYLURASES AND RELATED COMPOUNDS AND USE OF THE SAME
DK3177259T3 (en)	2020-03-23	CONNECTION AND CONTAINER SYSTEM
EP3349851A4 (en)	2019-04-24	PHOTOSENSITIVE POLYPEPTIDES AND METHODS OF USE
EP3119761C0 (en)	2023-06-07	AMYLOID-TARGETING AGENTS AND METHODS OF THEIR USE
DK3096798T3 (en)	2021-03-01	PLASMA CALLIC BINDING PROTEINS AND USES THEREOF FOR THE TREATMENT OF HEREDITARY ANGIOEDEM
EP3341027A4 (en)	2019-10-23	TRANSFECTION COMPLEXES AND METHODS OF USE
DK3197472T3 (en)	2021-10-18	RECOMBINANT PHE-FREE PROTEINS FOR USE IN THE TREATMENT OF PHENYLKETONURI
BR112017026398A2 (en)	2018-08-21	POLYETHYLENE FILM AND ARTICLE
EP3390676A4 (en)	2019-07-31	LIXIVIATION ADJUVANTS AND METHODS OF USE
DK3101760T3 (en)	2019-09-02	CHARGING PROCEDURE AND SYSTEM
EP3341017A4 (en)	2019-07-17	IMMUNOMODULATION COMPOSITIONS AND METHODS OF USE
EP3303436A4 (en)	2019-02-20	HYDROFLUOROOLEFINS AND METHODS OF USE

Legal Events

Date	Code	Title	Description
2017-05-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2017-08-04	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2017-08-04	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2017-09-06	17P	Request for examination filed	Effective date: 20170511
2017-09-06	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2017-09-06	AX	Request for extension of the european patent	Extension state: BA ME
2018-01-31	DAV	Request for validation of the european patent (deleted)
2018-01-31	DAX	Request for extension of the european patent (deleted)
2018-08-10	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1244460 Country of ref document: HK
2018-09-12	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 16/24 20060101ALI20180808BHEP Ipc: C07K 14/81 20060101ALI20180808BHEP Ipc: C07K 16/00 20060101ALI20180808BHEP Ipc: A61P 37/00 20060101AFI20180808BHEP
2019-01-23	A4	Supplementary search report drawn up and despatched	Effective date: 20190104
2019-01-23	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 37/00 20060101AFI20181220BHEP Ipc: C07K 16/24 20060101ALI20181220BHEP Ipc: C07K 16/00 20060101ALI20181220BHEP Ipc: C07K 14/81 20060101ALI20181220BHEP
2021-11-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2021-12-08	17Q	First examination report despatched	Effective date: 20211104
2023-06-28	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230523
2023-07-26	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: INHIBRX, INC.
2025-02-12	RAP3	Party data changed (applicant data changed or rights of an application transferred)	Owner name: SANOFI AATD INC.